Content Type: Article

  • California Supreme Court Decision Places Higher Burden on Employers in Whistleblowing Retaliation Claims

    California Supreme Court Decision Places Higher Burden on Employers in Whistleblowing Retaliation Claims

    ARTICLE / CLIENT ALERT

    California Supreme Court Decision Places Higher Burden on Employers in Whistleblowing Retaliation Claims

    February 1, 2022

    Read time: 4 min

    Key takeaways
    Overview

    On January 27, 2022, the California Supreme Court provided clarification in Lawson v. PPG Architectural Finishes, Inc. to lower courts reviewing whistleblower retaliation claims. In what it calls an “unsurprising” decision, the Supreme Court concluded that the framework prescribed by California Labor Code section 1102.6, rather than the McDonnell Douglas test, must be used in whistleblower claim evaluations.

    The impact of this decision is that employees will have a lower burden to meet to demonstrate that their alleged whistleblower activities resulted in an adverse employment action, while employers will have to meet a higher burden requiring them to demonstrate by clear and convincing evidence that they did not retaliate based on the employee’s activities.

     

    In depth

    Labor Code section 1102.6 requires that an employee bringing claims under Labor Code section 1102.5 for whistleblowing activities1 shows by a preponderance of the evidence that retaliation was a contributing factor in the employer’s adverse employment action. The burden then shifts to the employer to demonstrate by clear and convincing evidence that it would have taken the same action for legitimate, independent reasons even if the employee had not engaged in activities protected under Labor Code section 1102.5.

    By contrast, the McDonnell Douglas test required a plaintiff to establish a prima facie case by proving that they engaged in protected activity, that they were thereafter subjected to an adverse employment action and that there was a causal link between the two. Once the plaintiff established a prima facie case, the burden shifted to the employer to provide evidence of a legitimate, nondiscriminatory reason for the adverse employment action. The burden then shifted back to the employee to prove that the employer’s reason was pretextual.

    The Supreme Court’s decision makes clear that for any whistleblower retaliation claims brought under Labor Code section 1102.5, courts must apply the procedural framework listed in Labor Code section 1102.6. There are two main differences between the two frameworks. First, Labor Code section 1102.6 eases the burden on the plaintiff by only requiring a showing that the whistleblowing activity was a contributing factor to the employer’s adverse employment action, even when an employer might have other legitimate reasons for the adverse employment action.

    Second, Labor Code section 1102.6 places a heavier burden on employers by requiring them to show by clear and convincing evidence that they would have taken the same action for independent reasons. While the burden of persuasion under McDonnell Douglas stays with the plaintiff (who must continue to show that the reasons set forth by the employer are pretextual), this is not the case under Labor Code section 1102.6.

    Employers should keep in mind that this employee-friendly decision creates a higher burden on employers to show they did not act in a retaliatory manner for any employee whistleblower claims. If you have questions about the decision or how to navigate its implications, please do not hesitate to contact your regular McDermott Employment team.

    McDermott Will & Emery Law Clerk Priya Singh contributed to this article.


    1Under Labor Code section 1102.5, whistleblowing activities include but are not limited to: employees disclosing or providing information to a government agency, refusing to participate in activities what would violate state or federal statutes, and exercising their rights under their former employment.

    Authors

    Pankit J. Doshi

    Partner

    San Francisco, Silicon Valley

    More insights

  • State Law Privacy Video Series | Healthcare Entities and Health Data

    State Law Privacy Video Series | Healthcare Entities and Health Data

    ARTICLE / CLIENT ALERT / VIDEO

    State Law Privacy Video Series | Healthcare Entities and Health Data

    February 1, 2022

    Read time: 2 min

    Overview

    California, Virginia and Colorado have new privacy laws coming into effect in 2023. But now is the time to start preparing your business or organization for compliance.

    In this video series, we examine the different aspects of these laws and provide you the knowledge and tools you need for proper compliance.

    In depth

    In the below video, Partner Amy Pimentel discusses how these laws will impact health data and healthcare entities – in particular, those entities that are regulated by HIPAA.



    McDermott’s State Law Privacy Video Series: Healthcare Entities and Health Data overview, 2022 (runtime: 3m25s)

    Conclusion

    Amy C. Pimentel

    Partner

    Boston

    More insights

  • Antitrust M&A Snapshot | Q4 2021

    Antitrust M&A Snapshot | Q4 2021

    ARTICLE / REPORT

    Antitrust M&A Snapshot | Q4 2021

    January 31, 2022

    Read time: 2 min

    Overview

    McDermott Will & Emery’s global competition practice can assist clients with antitrust M&A issues in various jurisdictions around the world. Feel free to contact one or more of our partners in our various offices. The individuals below can assist or can refer you to one of our many other attorneys in our competition team who can help with a specific question.

    United States: Jon Dubrow, Joel Grosberg, Ray Jacobsen and Stephen Wu

    Europe: Jacques Buhart, David Henry, Christian Krohs, Frédéric Pradelles and Hendrik Viaene

    In depth
    Tabs

    Jon B. Dubrow

    Partner

    Washington, DC

    Joel R. Grosberg

    Partner

    Washington, DC

    Lisa P. Rumin

    Partner

    Washington, DC

    More insights
    Endnotes

  • 2021 FDA Year in Review

    ARTICLE / REPORT

    2021 FDA Year in Review

    January 2022

    Read time: 5 min

    Overview

    2021 was a dynamic year for the US Food and Drug Administration (FDA) as the agency continued to address the evolving COVID-19 public health crisis and associated challenges impacting the industry. Signs point to increased enforcement as we enter 2022 with a newly confirmed FDA commissioner, the withdrawal of many COVID-19 enforcement policies and the reorganization of key FDA divisions.

    Get the report for McDermott’s deep dive into 12 FDA-regulated areas and insights into the agency’s anticipated actions and priorities in 2022, including:

    • COVID-19
    • Drugs and biologics
    • Medical devices
    • Digital health
    • Enforcement
    • Investment and transaction trends.
    In depth

    The second year of the global COVID-19 pandemic contributed to a dynamic regulatory environment for the US Food and Drug Administration (FDA) and industry. FDA issued numerous guidance documents and enforcement policies in 2021 to address the evolving COVID-19 public health crisis and the resulting logistical challenges to manufacturing, supply chain and clinical development. The absence of a confirmed FDA commissioner and a unified policy agenda did not decrease the pace of regulation, particularly with respect to the agency’s response to continued innovation with renewed focus on real-world data, patient-centered product development and cybersecurity. While 2021 saw static or decreased FDA enforcement activity in traditional areas of focus, such as advertising and promotion and manufacturing, the withdrawal of many COVID-19 enforcement policies and the reorganization of key FDA divisions may signal increased enforcement in 2022.

    The Biden administration halted or rescinded several rulemakings and guidance issued at the 11th hour by the Trump administration. On January 20, 2021, the Biden administration issued a memorandum to the heads of executive departments and agencies indicating that it would postpone by 60 days the effective date of any rules issued but not in effect as of the date of the memorandum. While the administration has not formally extended the initial postponement, it took no action at the 60-day mark. The delay may reflect the need to shift resources to address the evolving impacts of COVID-19 on various regulatory processes and priorities. On January 20, 2021, the Biden administration also issued an executive order to withdraw any rules that did not publish in the Federal Register by noon that day. The current administration also found itself in the position of defending several lawsuits against Trump administration regulatory actions, many of which allege violations under the Administrative Procedures Act.

    While regulation continued apace, the absence of a permanent FDA commissioner throughout 2021 did result in the lack of a cohesive agency-wide policy agenda beyond the obvious concern for coping with the COVID-19 pandemic. Certain controversial areas such as the regulation of hemp and other cannabis-derived products have also been on the back burner, and several key agency positions such as the principal deputy commissioner, chief scientist and chief counsel have remained in an “acting” or vacant status. However, we have seen a cross-center shift prioritizing patient-centric regulatory decision making and patient care. Likewise, many industry stakeholders have shifted their marketing or commercial strategy to focus on patient-centered development, marketing and outreach, using strategies such as patient liaisons and direct outreach to patients or patient advocacy groups. FDA also has been developing guidance policies to incorporate real-world evidence (RWE) regarding patient experiences with various products into decision-making for new therapies.

    In mid-November 2021, the Biden administration formally nominated Robert M. Califf, MD, MACC, as FDA commissioner. Dr. Califf is the senior advisor for Verily and Google Health. Previously, Dr. Califf was the vice chancellor for health data science for the Duke University School of Medicine; director of Duke Forge, Duke’s center for health data science; and the Donald F. Fortin, MD, professor of cardiology. He is currently an adjunct professor of medicine at Duke. He served as deputy FDA commissioner for medical products and tobacco from 2015 to 2016, and as FDA commissioner from 2016 to 2017.

    During a Senate confirmation hearing in mid-December 2021, some members praised Dr. Califf for his thought leadership regarding clinical trials and potential to address concerns regarding the regulation of e-cigarettes head-on. However, he was also questioned about his ties to industry as a board member, adviser or investor, as well as his role as FDA commissioner amid the opioid drug crisis. On January 13, 2022, the Senate Committee on Health, Education, Labor and Pensions voted to advance Dr. Califf’s nomination to the full Senate. Therefore, the timing of a decision on Dr. Califf’s confirmation is unclear, but it will likely be within the next month, if not sooner.

    Tabs

    Michael W. Ryan

    Partner

    Washington, DC

    Alva C. Mather

    Partner

    Washington, DC

    More insights
    Endnotes

  • SEC Identifies Private Fund Deficiencies, Signifying Increased Industry Scrutiny

    SEC Identifies Private Fund Deficiencies, Signifying Increased Industry Scrutiny

    ARTICLE / CLIENT ALERT

    SEC Identifies Private Fund Deficiencies, Signifying Increased Industry Scrutiny

    January 31, 2022

    Read time: 9 min

    Key takeaways
    Overview

    On the heels of the SEC’s proposed rulemaking seeking increased disclosure from private fund advisers in Form PF,[1] the SEC’s Division of Examinations (“Exam Staff”) released a risk alert on Jan. 27, 2022 (“Risk Alert”),[2] highlighting common deficiencies identified during its examinations of private fund advisers.[3] In the Risk Alert, the staff pointed out that there has been a significant increase in private fund assets under management over the last five years. This has also been a theme in recent speeches by Chair Gary Gensler and the SEC’s Director of the Enforcement Division, Gurbir Grewal, making clear that under the stewardship of Chair Gensler, the SEC and its staff will be focused on the activities of private fund advisers in the near term. The findings in the Risk Alert are consistent with what we have observed on examination of private fund advisers.

    Four types of deficiencies are detailed in the Risk Alert: (1) failure to act consistent with disclosures, (2) use of misleading marketing materials, (3) failure to conduct adequate diligence of investments and service providers (including alternative data providers) and (4) the use of overly broad “hedge clauses.”

    Many of the deficiencies described in the Risk Alert could have been avoided with more careful attention to the interplay between the manager’s operations, disclosures and policies. A review of marketing practices is also warranted, not only in light of the Risk Alert, but also because of the upcoming advertising rule change.

    More broadly, private fund managers should carefully evaluate whether their practices are consistent with the positions described in the Risk Alert. Compliance professionals should also incorporate these points into the next annual compliance review and be prepared to address them with the Exam Staff in future examinations.

    Practices Inconsistent with Disclosures

    It has been nearly ten years since many private fund advisers were first required to register with the SEC. The Exam Staff now has extensive experience conducting examinations of private fund advisers. Its observations regarding disclosures reflect the evolution of the Exam Staff’s facility with private fund structure, terms and investment strategies. These observations also demonstrate that legal and compliance cannot be siloed – that is cannot be separate from the business at large. Instead, they must be involved sufficiently in the key business developments and transactions of the firm to seek to ensure they are conducted consistent with the relevant disclosures and the firm’s policies and procedures. In particular, a critical review of the operations, disclosures and policies relating to fee calculations, investment mandates, consent mechanics and other key points of potential friction within a fiduciary relationship should be undertaken.

    • LPAC Consent. The Exam Staff noted instances where advisers did not seek consent from advisory boards or limited partner advisory committees (together, “LPACs”) pursuant to disclosure provided in offering documents, due diligence questionnaires and other disclosure documents. Specifically, the Exam Staff identified conflicted transactions as an area where some private fund advisers did not engage with LPACs. Firms should have processes to both identify conduct that may require LPAC consent (as per fund disclosures or other requirements like principal transaction approval) and also make an informed decision as to whether consent is required and, if so, in what form.
    • Management Fee Calculation. The Risk Alert identifies inadequacies (i) in the calculation of post-commitment period fund-level management fees, particularly where advisers did not adjust the value of an investment “after selling, writing off, writing down or otherwise disposing of a portion of an investment” and (ii) where disclosures used undefined terms regarding investments that had been impaired or written down without sufficient policies and procedures addressing how such terms should be understood with respect to fee calculations.
    • Liquidation and Extension Provisions. The Exam Staff found that advisers extended fund lifetimes without obtaining approval as required in fund organizational documents, which caused advisers to earn management fees they may not have otherwise. The Exam Staff has in the past focused on so-called “zombie funds,” which are viewed as being extended far beyond their contemplated life so that advisers can charge additional fees.
    • Investment Strategy. The Risk Alert identifies that certain private fund advisers employed materially different investment strategies and exceeded limits on leverage as compared to what was disclosed in fund documents. Advisers to liquid strategies seeking to increase client exposure to private investments should be mindful of that exposure not only in light of their investment mandate but also in light of their redemption mechanics.
    • Private fund advisers were found to have inaccurately disclosed or omitted material information in their disclosures with respect to reinvestment of realized investment gains, which, in some instances, led to private fund investors incurring excess management fees.
    • Key Person Provisions. The Exam Staff also noted that certain private fund advisers did not adhere to key person provisions in their fund organizational documents, including not providing appropriate disclosure to investors regarding the departure of key investment professionals.

    Performance and Marketing Disclosures

    The calculation and display of performance information has consistently been the Exam Staff’s focus when assessing marketing materials; the findings in the Risk Alert are no exception. Private fund advisers should expect scrutiny whenever they are displaying hypothetical, predecessor or individual investment performance. Additionally, these findings serve as a precursor to the focus on advertising materials that is likely to come after the November 2022 compliance date for the SEC’s new marketing rule.

    • Track Records. The Exam Staff identified that many advisers did not accurately present performance track records. The Exam Staff found that many advisers cherry-picked certain fund performance, did not disclose the impact of leverage on returns and used performance that did not reflect the deduction of fees and expenses.
    • Performance Calculations. Many private fund advisers were identified as having inaccurately calculated performance returns, by, among other things, calculating the performance over the wrong time period, mischaracterizing the return of capital from portfolio companies and incorporating projected rather than actual performance.
    • Predecessor Performance. The Risk Alert identifies that many advisers did not maintain the books and records underlying performance as required under Rule 204-2 and utilized track records in marketing materials for which advisory personnel were not primarily responsible. In our experience, the Exam Staff has been very focused on the portability of track records. Private fund advisers must be able to demonstrate that their use of predecessor performance comports with the applicable guidance (and the new marketing rule as of its compliance date in November).
    • Many advisers were also identified as having made misleading statements regarding awards they had received, and had not included requisite disclosure regarding the criteria for obtaining the awards and fees paid in connection with receiving or marketing receipt of the award.

    Investment Diligence

    The Exam Staff expressed concern that private fund advisers were not meeting their fiduciary duty, in part, because they did not have a reasonable belief that investment advice was in the best interest of their clients as supported by a reasonable investigation into investment opportunities pursued. In the Risk Alert, the Exam Staff identified that certain private fund advisers did not conduct sufficient diligence on investments or employ policies and procedures designed to ensure appropriate diligence was conducted.

    The research and investment process at private fund advisers is dynamic and multi-faceted, and there is no uniform approach to recordkeeping when it comes to investment diligence. Different investment strategies entail very different types of diligence. However, it is typical that Exam Staff will request during an examination that advisers provide research files with respect to their investments. An inability to demonstrate that an adviser’s investment decisions are based on reasonable diligence can lead to the types of deficiencies identified by the Exam Staff and can create concern among the Exam Staff that investment decisions are being made on a basis other than sound diligence (i.e., material non-public information).

    The Risk Alert also highlights the importance of diligence of service providers, specifically noting alternative data providers and placement agents. The proliferation of alternative data and its increasing importance in the investment process create diligence challenges for advisers. The Exam Staff has been working on a risk alert with respect to alternative data, but, in the meantime we see increased scrutiny during examinations of advisers’ use of such data.

    Hedge Clauses

    In the Risk Alert, the Exam Staff identified that certain advisers included in client agreements potentially misleading provisions that sought to waive the fiduciary duty except for certain exceptions, “such as a non-appealable judicial finding of gross negligence, willful misconduct, or fraud.” The Risk Alert notes that whether such a clause violates the antifraud provisions of the Advisers Act will depend on all of the surrounding facts and circumstances. The Exam Staff cites the 2019 Commission Interpretation Regarding the Standard of Conduct for Investment Advisers, which indicated that although “blanket” waivers of fiduciary duties are impermissible, fiduciary duties must be viewed in the agreed-upon context of the particular client and adviser.

    Authored by Marc E. Elovitz, Kelly Koscuiszka and Tarik M. Shah.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] “SEC Proposes Substantial Increases to Form PF Reporting,” SRZ Alert, Jan. 26, 2022, available here.

    [2] “Observations from Examinations of Private Fund Advisers,” Division of Examinations Risk Alert, Jan. 27, 2022, available here.

    [3] The Risk Alert follows a June 2020 risk alert that addressed common exam deficiencies related to conflicts of interest, MNPI and Code of Ethics violations and fees and expenses, available here.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2022 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Marc E. Elovitz

    Partner

    New York – 919 Third Avenue

    Kelly Koscuiszka

    Partner

    New York – 919 Third Avenue

    Tarik M. Shah

    Partner

    New York – 919 Third Avenue

    More insights

  • Washington State’s Mandatory Withholding for Long-Term Care Put on Hold

    Washington State’s Mandatory Withholding for Long-Term Care Put on Hold

    ARTICLE / CLIENT ALERT

    Washington State’s Mandatory Withholding for Long-Term Care Put on Hold

    January 27, 2022

    Read time: 4 min

    Key takeaways
    Overview

    In 2019, the Washington State Legislature (Legislature) established the Long-Term Services and Supports Trust Program (LTSS Trust Program) to provide funding for eligible beneficiaries that they can apply to the cost of their long-term care. The LTSS Trust Program is funded through a 0.58% payroll tax on employee wages, which went into effect on January 1, 2022.

    Though the LTSS Trust Program was intended to provide a baseline of benefits to Washingtonians lacking private long-term care insurance, the program drew public criticism in recent months because, among other things, employees had no easy way to opt out of it. The legislation provided that individuals could opt out by purchasing private long-term care insurance before November 1, 2021, and applying for an exemption by the end of 2021. However, shortly after the program went into law, most (if not all) private long-term care insurance providers pulled out of the state.

    When the Legislature convened earlier this month, it fast-tracked new legislation to put the LTSS Trust Program on hold. Though many lawmakers were calling for an outright repeal of the program, the majority ultimately passed a bill to delay its implementation until July 2023. Washington Governor Jay Inslee is expected to sign the measure by Friday, January 28.

    Since this delay comes after employers have already started withholding the tax from their employees’ wages and, in some cases, after the tax has been remitted to the Employment Security Department (ESD), refunds will be necessary. Under the new law, employers are required to provide refunds to their employees within 120 days of the collection. If the employer already remitted the tax to the ESD, the ESD is required to refund that money to the employer who is then required to pass it on to the employee.

    If you have questions about the LTSS Trust Program or its delayed implementation, please contact the author of this article.

    In depth

    In 2019, the Washington State Legislature (Legislature) established the Long-Term Services and Supports Trust Program (LTSS Trust Program) to provide funding for eligible beneficiaries that they can apply to the cost of their long-term care. The LTSS Trust Program is funded through a 0.58% payroll tax on employee wages, which went into effect on January 1, 2022.

    Though the LTSS Trust Program was intended to provide a baseline of benefits to Washingtonians lacking private long-term care insurance, the program drew public criticism in recent months because, among other things, employees had no easy way to opt out of it. The legislation provided that individuals could opt out by purchasing private long-term care insurance before November 1, 2021, and applying for an exemption by the end of 2021. However, shortly after the program went into law, most (if not all) private long-term care insurance providers pulled out of the state.

    When the Legislature convened earlier this month, it fast-tracked new legislation to put the LTSS Trust Program on hold. Though many lawmakers were calling for an outright repeal of the program, the majority ultimately passed a bill to delay its implementation until July 2023. Washington Governor Jay Inslee is expected to sign the measure by Friday, January 28.

    Since this delay comes after employers have already started withholding the tax from their employees’ wages and, in some cases, after the tax has been remitted to the Employment Security Department (ESD), refunds will be necessary. Under the new law, employers are required to provide refunds to their employees within 120 days of the collection. If the employer already remitted the tax to the ESD, the ESD is required to refund that money to the employer who is then required to pass it on to the employee.

    If you have questions about the LTSS Trust Program or its delayed implementation, please contact the author of this article.

    Authors

    Troy M. Van Dongen

    Partner

    San Francisco

    More insights

  • Sixth Circuit Endorses Sealing of Filings to Protect Confidentiality of Alleged Trade Secrets

    Sixth Circuit Endorses Sealing of Filings to Protect Confidentiality of Alleged Trade Secrets

    ARTICLE

    Sixth Circuit Endorses Sealing of Filings to Protect Confidentiality of Alleged Trade Secrets

    Jan 27, 2022

    Read time: 2 min

    Key takeaways
    Overview

    On appeal from a dismissal based on a failure to state a claim for misappropriation of trade secrets, the US Court of Appeals for the Sixth Circuit granted the litigants’ motion to seal their briefs and file publicly available redacted versions in order to protect the confidentiality of the appellant’s alleged trade secrets. Magnesium Machine, LLC v. Terves, LLC, Case No. 20-3998 (6th Cir. Jan. 14, 2022) (Donald, J.)

    The Sixth Circuit reasoned that the case had been brought under the Defend Trade Secrets Act, which requires courts to take “action as may be necessary and appropriate to preserve the confidentiality of trade secrets.” The Court also relied on precedent to the effect that trade secrets generally provide a justification (i.e., a “compelling reason”) for sealing. The Court left open the possibility of reconsidering its ruling if it later determines that any of the redacted information should be made available to the public.

    Practice Note: Public disclosure—even in a court document—can destroy a trade secret. Litigants should be careful when disclosing information that is even alleged to be a trade secret, even if they are not certain whether the information qualifies as a trade secret since, if and when litigated, the information may later be held to qualify.

    Authors

    Paul Devinsky

    Senior Counsel

    Washington, DC

    More insights
    Endnotes

  • EU Shorting Threshold Transition from 28 to 31 January 2022

    EU Shorting Threshold Transition from 28 to 31 January 2022

    ARTICLE / CLIENT ALERT

    EU Shorting Threshold Transition from 28 to 31 January 2022

    January 27, 2022

    Read time: 3 min

    Key takeaways
    Overview

    The European Securities and Markets Authority (“ESMA”) has published guidance on how to treat net short positions in EU-listed shares in anticipation of the transition to the lower 0.1% threshold.

    As stated in our previous Alert,[1] with effect from 31 January 2022, the initial threshold for notification of net short positions in EU-listed companies will be lowered from 0.2% to 0.1% of a company’s issued share capital. ESMA has now confirmed that the last day of application of the old reporting threshold (0.2%) will be in relation to positions held on Friday 28 January 2022, with the Friday’s net short positions to be reported to the EU’s relevant competent authorities by 3:30 pm (local time) on Monday 31 January 2022.

    The first day on which the 0.1% position reports are due is Tuesday 1 February 2022. By way of example, net short positions must be reported on Tuesday if the net short position was:

    1. i) less than 0.2% (including no position at all) at the end of Friday 28 January and 0.1% or more at the end of Monday 31 January; or
    2. ii) 0.2% or more on Friday 28 January but subsequently reduced to 0.1% or less on Monday 31 January. This would be the case even if at the end of Monday the position is under 0.1%, in which case the report would have to indicate that the position crossed the 0.1% threshold downwards.

    ESMA’s statement here includes a number of other illustrative examples for different types of scenarios.

    Authored by Anna Maleva-Otto and David Soerensen.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] /insights/eu-shorting-threshold-lowered-to-0-1-from-31-january-2022/


    This communication is issued by Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2022 Schulte Roth & Zabel LLP and Schulte Roth & Zabel International LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors
    More insights

  • California to Renew COVID-19 Supplemental Paid Sick Leave for 2022

    California to Renew COVID-19 Supplemental Paid Sick Leave for 2022

    ARTICLE / CLIENT ALERT

    California to Renew COVID-19 Supplemental Paid Sick Leave for 2022

    January 26, 2022

    Read time: 2 min

    Key takeaways
    Overview

    On January 25, 2022, California Governor Gavin Newsom announced that his office and state lawmakers had reached an agreement to reimplement a version of California’s COVID-19 Supplemental Paid Sick Leave through September 30, 2022. The governor’s press release can be found here.

    In depth

    It is expected that the state legislature will move quickly to finalize and vote on legislation to effectuate this statewide paid leave obligation. The governor’s office did not announce further details; however, various news sources have reported the following details from the proposed legislation:

    • Paid leave obligations apply to employers with more than 25 employees.
    • COVID-19-related paid leave obligations will be retroactive to cover absences beginning January 1, 2022, with an expiration date of September 30, 2022.
    • Covered employers would be required to provide workers with up to two weeks of supplemental paid sick leave to recover from COVID-19 or care for a family member with the virus, as follows:
      • Up to 40 hours of flexible paid leave for full-time workers who are sick or caring for an ill loved one; and
      • Up to 40 additional hours of paid leave with proof of a positive COVID-19 test.

    The proposed legislation details above are subject to change as the legislation is finalized and voted on in the coming weeks.

    McDermott Will & Emery is closely tracking this legislation and is available to assist employers with paid leave policy updates and continued compliance efforts.

    Authors
    More insights

  • SEC Proposes Substantial Increases to Form PF Reporting

    SEC Proposes Substantial Increases to Form PF Reporting

    ARTICLE / CLIENT ALERT

    SEC Proposes Substantial Increases to Form PF Reporting

    January 26, 2022

    Read time: 3 min

    Key takeaways
    Overview

    The Securities and Exchange Commission is proposing significant increases to reporting by hedge and PE fund advisers on Form PF. More details and analysis to come, but the key points identified by the SEC in voting to make the proposal are as follows:

    Current Reporting of Certain Events by Large Hedge Fund Advisers. Large hedge fund advisers would be required to file current reports within one business day of the occurrence of one or more reporting events with respect to their qualifying hedge funds:

    • 20% or more losses
    • Significant margin and counterparty default events
    • Material changes in prime brokerage relationships
    • Changes in unencumbered cash, operations events and events associated with withdrawals and redemptions

    Current Reporting of Certain Events by Private Equity Fund Advisers. Private equity fund advisers would be required to file current reports within one business day of the occurrence of one or more reporting events pertaining to:

    • The execution of adviser-led secondary transactions
    • Implementation of general partner or limited partner clawbacks
    • Removal of a fund’s general partner, termination of a fund’s investment period
    • Termination of a fund

    Reducing Threshold for Large Private Equity Adviser Reporting. The threshold for reporting as a large private equity adviser would be reduced from $2 billion to $1.5 billion in private equity fund assets under management.

    Additional Reporting by Large Private Equity Advisers. The proposal would amend Section 4 of Form PF for large private equity advisers to gather more information regarding fund strategies, use of leverage and portfolio company financings, controlled portfolio companies (“CPCs”) and CPC borrowings, fund investments in different levels of a single portfolio company’s capital structure and portfolio company restructurings or recapitalizations.

    Additional Reporting by Large Liquidity Fund Advisers. The proposed amendments would require large liquidity fund advisers to report substantially the same information that money market funds would report on Form N-MFP, as the SEC proposes to amend it.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2022 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors
    More insights